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Etoposide (VP-16) is a topoisomerase II (topo II) inhibitor chemotherapeutic agent. Studies indicate that VP-16 enhances
proinflammatory cytokines secretion from tumour cells, including IL-8, a chemokine associated with proangiogenic effects.
Fluoroquinolones inhibit topo II activity in eukaryotic cells by a mechanism different from that of VP-16. The fluoroquinolone
moxifloxacin (MXF) has pronounced anti-inflammatory effects in vitro and in vivo. We studied the effects of MXF and VP-16 on
purified human topo II activity and further analysed their combined activity on proliferation, apoptosis and caspase-3 activity in THP-1
and Jurkat cells. Moxifloxacin alone slightly inhibited the activity of human topo II; however, in combination with VP-16 it led to a 73%
reduction in enzyme activity. VP-16 inhibited cell proliferation in a time and dose-dependent manner. The addition of moxifloxacin
for 72h to low-dose VP-16 doubled its cytotoxic effect in THP-1 and Jurkat cells (1.8- and 2.6-fold decrease in cell proliferation,
respectively) (Po0.004). Moxifloxacin given alone did not induce apoptosis but enhanced VP-16-induced apoptosis in THP-1 and
Jurkat cells (1.8- and two-fold increase in annexin V positive cells and caspase-3 activity, respectively) (Po0.04). VP-16 induced the
release of IL-8 in a time and dose-dependent manner from THP-1 cells. Moxifloxacin completely blocked the enhanced release of IL-
8 induced by 0.5 and 1mgml
 1 VP-16, and decreased IL-8 release from cells incubated for 72h with 3mgml
 1 VP-16 (Po0.001). VP-
16 enhanced the release of IL-1b and TNF-a from THP-1 cells, whereas the addition of MXF prevented the enhanced cytokine
secretion (Po0.001). We conclude that MXF significantly enhances VP-16 cytotoxicity in tumour-derived cells while preventing VP-
16-induced proinflammatory cytokine release. This unique combination may have clinical benefits and cytotoxic drug ‘sparing effect’
and should be further studied in vivo.
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Topoisomerase II (topo II) is an important target of chemother-
apeutic agents (Berger and Wang, 1996). One of the first drugs to
demonstrate an antineoplastic effect through inhibition of topo II
was etoposide (VP-16), which prevents resealing of the enzyme-
linked DNA breaks (Handle, 1998). Etoposide is used today as
frontline therapy for a variety of human malignancies, including
leukaemias, lymphomas and several solid tumours (Fry et al, 1991;
Handle, 1998).
Several studies have indicated that in addition to their known
cytotoxic effects, many chemotherapeutic agents, including VP-16,
are also prooxidative stressors (Kagan et al, 2001) and trigger
cytokine production in a variety of cell types in vitro (Kawagishi
et al, 2001; Darst et al, 2004). These findings were supported by
reports of significant levels of proinflammatory cytokines in
patients undergoing chemotherapy for a variety of tumours
(Villani et al, 2002). The role of proinflammatory cytokines in
tumour progression, angiogenesis and metastases has been
elucidated in recent years. Specifically, IL-8 was shown to be a
potent proangiogenic factor associated with increased microvessel
count, increased VEGF expression and poor prognosis in
oesophageal squamous cell carcinoma, colonic cancer cells and
pancreatic adenocarcinoma cells (Mizukami et al, 2005; Ren et al,
2005; Trevino et al, 2005). Various studies have shown that
blocking IL-8 expression reversed many of these proangiogenic
and metastatic cell activities, further supporting the important role
of this proinflammatory cytokine in tumour progression ((Mizu-
kami et al, 2005; Ren et al, 2005; Trevino et al, 2005).
Combination chemotherapy is commonly employed for treat-
ment of many neoplastic diseases and is considered to provide
several advantages over single-agent regimens.
Fluoroquinolones are highly effective antibiotics with a broad
antibacterial spectrum (Bakshi et al, 2001). At high concentrations,
some fluoroquinolones exhibit genotoxic effects in eukaryotic
systems as a result of topo II inhibition (Robinson et al, 1991).
Quinolone-induced inactivation of topo IIa at high concentrations
was proposed to involve the direct binding of quinolones to DNA Revised 11 August 2006; accepted 11 August 2006
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sand their mode of inhibition was shown to be distinct from the
inhibitory mechanism of agents like VP-16 (Bromberg et al,
2003a). Additional studies suggest that quinolones such as CP-
115953 enhance the formation of double-stranded DNA breaks by
human topo IIa and exert cytotoxic activity in Chinese hamster
ovary cells (Elsea et al, 1997). Our group and others assessed the in
vitro activity of certain quinolones against various tumour cell
lines. Ciprofloxacin was found to inhibit tumour cell growth of
bladder transitional cell carcinoma, colon cancer and prostate
cancer cell lines at concentrations achievable with its oral
administration (Zehavi-Willner and Shalit, 1992; Shalit et al,
1995; Herold et al, 2002; Aranha et al, 2003).
We have previously shown that the fluoroquinolone moxiflox-
acin (MXF) inhibits nuclear factor kappa B (NF-kB) activation,
mitogen-activated protein kinase activation and synthesis of the
proinflammatory cytokines IL-8, TNF-a and IL-lb in activated
human monocytic cells (Weiss et al, 2004). It also had a protective
anti-inflammatory effect in vivo in a model of Candida albicans
pneumonia in immune suppressed animals, resulting in enhanced
survival and reduction in IL-8 and TNF-a in lung homogenates
(Shalit et al, 2002). In the present study, we investigated the effect
of MXF alone and in combination with VP-16 on isolated human
topo IIa activity and further studied the effect of the combination
on cell proliferation, cytotoxicity and apoptosis in two tumour-
derived cell lines, THP-1 and Jurkat. In parallel, we investigated the
effect of MXF on VP-16-induced release of proinflammatory
cytokines, including IL-8, in these cells.
MATERIALS AND METHODS
Human topo II assay
A previously described method was used with slight modifications
(Bendetz-Nezer et al, 2004). Purified human DNA topo II (p170)
(0.5–2 units) (TopoGen Inc., Port Orange, FL, USA) was added to
a topo II reaction mixture containing, at a final volume of 20ml,
50mM Tris-HCl, (pH 8), 0.5mM dithiothreitol (DTT), 120mM KCl,
10mM MgCl2, 0.5mM EDTA, 25mgml
 1 bovine serum albumin,
1m M ATP and 250–750ng of pUC 19 supercoiled DNA plasmid
(MBI Fermentas, Hanover, MD, USA). Different concentrations of
MXF (20–100mgml
 1) and VP-16 (5–10mgml
 1) were added.
After incubation at 371C for 10min, the reaction was terminated by
adding 5ml of stopping buffer (final concentration, 1% SDS, 15%
glycerol, 0.5% bromphenol blue and 50mM EDTA, pH 8). The
reaction products were analysed by electrophoresis on 1% agarose
gel using a Tris-borate/EDTA buffer (89mM boric acid and 62mM
EDTA) at 1Vcm
 1, stained with ethidium bromide (1mgml
 1),
and photographed using a short-wavelength UV lamp (Chemi-
Imager 5500; Alpha Innotech, San Leandro, CA, USA).
Cell lines
Human acute monocytic leukaemia cell line THP-1 (ATCC TIB
202) and human acute T-cell leukaemia Jurkat cells were
maintained in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum, 2mML -glutamine, 100unitsml
 1
penicillin and 100mgml
 1 streptomycin at 371C in a humidified
incubator with 5% CO2.
Cytotoxicity assay
THP-1 and Jurkat cells, cultured as described above, were seeded
on 96-well plates (at a concentration of 5 10
4 THP-1 cells per
0.1mlwell
 1 and 2.5 10
4 Jurkat cells per 0.1mlwell
 1)i n
triplicate, and various concentrations of MXF, VP-16 and their
combination were added. The cells were incubated for 24–72h at
371Ci n5 %C O 2 atmosphere. For the last 3h of incubation, MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) (5mgml
 1)
in phosphate-buffered saline (PBS) was added to each well. The
cells were incubated at 371C for 3h and 0.04 M HCl was added to
dissolve the formazan crystals. The absorbance was then measured
at 560nm with a spectrophotometer (ELISA Reader Molecular
Devices Corporation, Sunnyvale, CA, USA).
Apoptosis assay
Apoptosis was measured by flow cytometry after concurrent
staining with fluorescein-conjugated annexin V and propidium
iodide (PI), as previously described (Gross-Fischer and Fabian,
2002). In brief, following incubation of THP-1 and Jurkat cells with
1mgml
 1 VP-16 and various concentrations of MXF and their
combination for 24h, cells were collected and washed with cold
PBS and resuspended in annexin V-PI binding buffer (10mM
HEPES, pH 7.4, 140mM NaCl, 2.5mM CaCl2). An aliquot of 100ml
was removed and mixed with 4ml of annexin V-PI. The mixture
was incubated for 15min at room temperature (RT) in the dark.
The cells were then washed once with binding buffer, resuspended
in binding buffer and subjected to flow cytometric analysis on
FACScan (Becton Dickinson, Franklin Lakes, NJ, USA).
Fluorogenic assay for caspase-3 activity
Caspse-3 was measured as previously described by us (Gross-
Fischer and Fabian, 2002). THP-1 and Jurkat cells were incubated
for 24h with 1 and 3mgml
 1 VP-16 or various concentrations of
MXF, or combination of both drugs. Following incubation, the
cells were collected, washed, resuspended in 50mM HEPES (pH
7.4), 0.1% CHAPS, 5mM DTT and 0.1mM EDTA, incubated for
15min on ice and lysed by three successive freeze–thaw cycles at
dry ice/371C. Cell lysates were centrifuged at 14000r.p.m. for
15min, and the supernatants were stored at  701C. The protein
concentration of each sample was estimated using the Bradford
Bio-Rad protein assay. For caspase-3 activity, a total of 25mg
protein was incubated with 30mM ac-DEVD-AMC (BIOMOL
Research Laboratories, Plymouth Meeting, PA, USA) at 371C, for
60min in the dark. The release of 7-amino-4-methylcoumarine was
monitored by a spectrofluorometer using an excitation wavelength
of 360nm and an emission wavelength of 460nm. In some
experiments, a caspase-3 inhibitor (Z-DEVD-FMK, Calbiochem,
Nottingham, UK) was added directly to the medium 30min before
the addition of 1mgml
 1 VP-16.
Western blot analysis of caspase-3
For caspase-3 immunoblotting, total cell lysates were prepared as
described before with slight modifications. Cells were collected and
washed twice in ice-cold PBS, and then lysed with a solubilising
solution on ice for 30min (Gross-Fischer and Fabian, 2002). The
extracts were cleared by centrifugation. Equal amounts of protein
(50mg) were subjected to electrophoresis on 12% SDS–poly-
acrylamide gel and then electrophoretically transferred to a
nitrocellulose membrane. The membranes were incubated with
anti-caspase-3 polyclonal antibody (diluted 1:1000, PharMingen,
Franklin Lakes, NJ, USA). Actin levels were also assessed as a
loading control using an antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) that reacts with a broad range of actin
isoforms. The blots were then incubated with a secondary
antibody, horseradish peroxidase-linked anti-mouse IgG (Santa
Cruz Biotechnology). After 1h at RT and three washes in TBST, the
blots were incubated in enhanced chemiluminescence reagent (ECL,
Amersham Pharmacia Biotech, Uppsala, Sweden). Bound antibodies
were visualised following chemiluminescence detection on auto-
radiographic film.
IL-8, IL-1b and TNF-a production analysis by ELISA
THP-1 cells suspended in RPMI medium, as described above, were
placed in 24-well culture plates at a concentration of
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6cellsml
 1 (for the determination of IL-8) and incubated for
24–72h with various concentrations of VP-16 in the presence or
absence of 5–20mgml
 1 MXF. For the determination of IL-1b and
TNF-a, cells were plated at concentrations of l 10
6cellsml
 1 and
1.5 10
6cellsml
 1, respectively, for 24h in the presence of VP-16
and MXF as described above. Cell-free supernatants were
recovered, and the concentrations of IL-8, IL-1b and TNF-a were
determined using ELISA (R&D Systems Inc., Minneapolis MN,
USA). The sensitivity of the assay for IL-8 is 410pgml
 1, for IL-
1b 44pgml
 1 and for TNF-a 415pgml
 1. Jurkat cells were
pretreated for 1h with 1–10ngml
 1 phorbol myristate acetate
(PMA) and 5–500ngml
 1 ionomycin (Sigma Chemical Co., St
Louis, MO, USA) to promote cytokine production (Pestka et al,
2005). Various concentrations of VP-16 and MXF were added and
the concentrations of IL-8, IL-1b and TNF-a were determined as
described above.
Statistical analysis
Statistical significance was determined by paired t-test (for MTT,
fluorogenic assay for caspase-3 activity and for cytokine secretion)
and ANOVA: two-factor without replication test (for the annexin-
PI studies). A P-value of p0.05 was considered significant.
RESULTS
Purified human topo II DNA relaxation activity assay
The inhibition of the DNA relaxation activity of human topo II by
various concentrations of MXF and VP-16 was investigated using
purified human topo II added to a specific reaction mixture
containing ATP and supercoiled pUC 19 DNA as the substrate, as
described in Materials and Methods. As shown in Figure 1A, MXF
at a concentration of 20 and 40mgml
 1 caused a 5–6% inhibition
of topo II activity (lanes 3 and 4, respectively). Etoposide reduced
topo II activity only slightly at a concentration of 10mgml
 1 (10%)
(lane 6), and not at all at a lower concentrations (5mgml
 1) (lane
5). By contrast, the combination of 20mgml
 1 MXF with 5 or
10mgml
 1 VP-16 markedly reduced topo II activity, by 20% (lane
7) and 67% (lane 8), respectively. The combination of a higher
concentration of MXF (40mgml
 1) with VP-16 revealed only a
slight further inhibition of topo II activity (up to 73%) (lane 10).
The observed increased inhibitory effect of VP-16 by MXF might
be due to (1) a direct effect of MXF on the topo II protein,
rendering it more susceptible to the action of VP-16; (2) MXF
affects the DNA (e.g. intercalation) in a way that increases the VP-
16-induced stabilisation of the DNA–enzyme cleavable complexes.
To determine which of the possibilities do occur, we performed
two classical biochemical competition-based assays (Aflalo et al,
1994). Topoisomerase II activity was measured in the presence of
constant amounts of DNA and MXF/VP-16 and increasing
amounts of topo II enzyme (Figure 1B) or vice versa; topo II
activity was measured in the presence of constant amounts of
enzyme and MXF/VP-16 and increasing amounts of DNA
(Figure 1C). The results show that only by increasing the amount
of topo II enzyme, it is possible to overcome the inhibitory effect of
MXF/VP-16 (Figure 1B compared to 1C), suggesting a possible, yet
unclear, interaction of MXF with the topo II protein.
On the basis of our observations that MXF enhances the
inhibition of purified topo II activity conferred by VP-16, we
investigated the possible association between the effect on isolated
topo II activity and the cytotoxic activity of the drug combination.
Effect of MXF on the antiproliferative action of VP-16
We performed time-dependent studies on the effect of VP-16
(0.5mgml
 1) on the proliferation of THP-1 cells. Figure 2A
indicates that a decrease of 17.770.2 and 2970.3% was observed
upon incubation of the cells with the drug for 48 and 72h,
respectively (Po0.001). Moxifloxacin given alone, at concentra-
tions of 5 or 10mgml
 1 did not affect cell proliferation (data not
shown) whereas incubation of the cells with 20mgml
 1 MXF for
24–72h resulted in a 1670.1–2070.4% inhibition in cell
proliferation (Po0.05).
A significant decrease in cell proliferation was seen with the
combination of 0.5mgml
 1 VP-16 and MXF compared to VP-16
alone. Upon exposure of the cells to a combination of VP-16 and
10mgml
 1 MXF for 48 and 72h, a marked decrease in cell
proliferation (up to 3670.6 and 4570.8%, respectively) was
observed (P¼o0.001). Maximum inhibition in cell proliferation
was observed upon incubation of the cells with 0.5mgml
 1 VP-16
and 20mgml
 1 MXF for 72h (up to 5270.5%), compared to VP-16
alone (Po0.001) (Figure 2A).
Dose-dependent studies of VP-16 and MXF were performed,
following incubation of the cells for 48h with the drugs. Exposure
of THP-1 cells to VP-16 for 48h resulted in a concentration-
dependent decrease in cell proliferation (Figure 2B). It should be
noted that exposure of THP-1 cells to a low dose of the cytotoxic
drug VP-16 (0.5mgml
 1) and 20mgml
 1 MXF resulted in a 46%
inhibition of cell proliferation, similar to the inhibitory effect of
1mgml
 1 VP-16 alone (41%). Maximal inhibition of cell prolifera-
tion was observed upon incubation of the cells with 3mgml
 1 VP-
16 and 20mgml
 1 MXF compared to VP-16 alone (85.471.6 vs
7671.5%, respectively, P¼0.006).
In Jurkat cells (Figure 2C), incubation of the cells for 72h with a
low dose of VP-16 (0.5mgml
 1), resulted in a 2170.6% inhibition
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Figure 1 (A) Representative agarose gel electrophoresis analysis of the
topo II reaction products, obtained with increasing amounts of MXF, VP-16
or their combination. The pUC supercoiled DNA plasmid and the relaxed
forms are shown. (B) Increasing amounts of topo II (0.5–2 units) were
added to reaction mixtures containing a constant amount of pUC19 DNA
(250ng) and 10mgml
 1 VP-16þ40 or 100mgml
 1 MXF. (C) Increasing
amounts of pUC-19 DNA (500–750ng) were added to topo II reaction
mixture containing constant amounts of topo II (1 unit) and 10mgml
 1 VP-
16þ40mgml
 1 MXF. R¼relaxed DNA, S¼supercoiled DNA, u¼units.
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sof cell proliferation (Po0.001). As with THP-1 cells, incubation of
Jurkat cells with 5 or 10mgml
 1 MXF for 24–72h, did not affect
cell proliferation (data not shown), whereas incubation for 72h
with 20mgml
 1 MXF, resulted in a 2470.6% inhibition of cell
proliferation (P¼0.008). Exposure of the cells for 72h to a
combination of VP-16 (0.5mgml
 1) and 10 or 20mgml
 1 MXF, led
to 3170.1 and 5470.5% inhibition, respectively, compared to
2170.6% with VP-16 alone (Po0.004).
The addition of various concentrations of VP-16 alone reduced
cell proliferation in a dose-dependent manner (Figure 2D). Like in
THP-1 cells, the addition of increasing concentrations of MXF to
Jurkat cells incubated for 48h with various concentrations of VP-
16 further decreased cell proliferation. Incubation of the cells with
1mgml
 1 VP-16 and 20mgml
 1 MXF resulted in 5675% decrease,
compared to 2272% for VP-16 alone (P¼o0.001). The maximal
inhibition of cell proliferation was observed upon incubation of
the cells with 3mgml
 1 VP-16 and 20mgml
 1 MXF (up to 8978%)
(Figure 2D).
Effect of MXF on VP-16-induced apoptosis
Phosphatidylserine, which is normally confined to the inner leaflet
of the plasma membrane, is exported to the outer plasma
membrane leaflet during apoptosis. We assessed phosphatidyl-
serine externalisation following the exposure of THP-1 and Jurkat
cells for 24h to MXF alone or to 1mgml
 1 VP-16 in the presence or
absence of 5–20mgml
 1 MXF. As shown in Figure 3A and C, in the
THP-1 cells, MXF (20mgml
 1) given alone, did not affect apoptosis
whereas a marked increase in apoptotic (annexin V-positive) cells
was observed after exposure to VP-16, and a further 1.7-fold to 1.8-
fold increase with the addition of 5–20mgml
 1 MXF (P¼0.038).
As with THP-1 cells, exposure of Jurkat cells to 20mgml
 1 MXF
did not affect apoptosis whereas exposure to 1mgml
 1 VP-16 alone
(Figure 3B) resulted in a mild increase in apoptotic cells, with a
further increase after the addition of MXF, by 1.7-fold for
10mgml
 1 MXF (P¼0.024), and by 2.2-fold for 20mgml
 1 MXF
(P¼0.015) (Figure 3C).
Caspase-3 activation
DEVD-AMC is a specific substrate for caspase-3 that mimics the
PARP cleavage site. To test caspase-3 activation, cell lysates from
THP-1 and Jurkat cells that were treated with VP-16 in the
presence or absence of 5–20mgml
 1 MXF for 24h were incubated
with the substrate, and the increase in fluorescence due to
enzymatic cleavage of the peptides was measured with a
fluorometer. As shown in Figure 4A, in THP-1 cells, treatment
with 1 or 3mgml
 1 VP-16 significantly increased caspase-3
activation (P¼0.011 and P¼0.044, respectively). The addition of
20mgml
 1 MXF further enhanced this increase by two-fold in the
presence of 1mgml
 1 VP-16 (P¼0.045) and by 1.7-fold in the
presence of 3mgml
 1 VP-16 (P¼0.05). To confirm that the
caspase activity observed was specific to caspase-3, we used a
caspase-3-specific inhibitor, Z-DEVD-FMK. Treatment of cells
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Figure 2 Moxifloxacin enhances the antiproliferative effect of VP-16. Time-dependent studies: THP-1 cells (A) and Jurkat cells (C) were incubated for
24–72h with 0.5mgml
 1 VP-16 in the presence or absence of various concentrations of MXF. Cell proliferation was determined by colorimetric MTT assay.
Dose-dependent studies: THP-1 cells (B) and Jurkat cells (D) were incubated for 48h in the presence of the indicated concentrations of VP-16 and MXF.
Cell proliferation was determined as described above. Results are expressed as mean7s.e. of four experiments performed in triplicate. *Po0.05 cells
treated with drugs vs control. **Po0.007 for cells treated by VP-16þMXF vs VP-16 alone.
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Figure 3 Moxifloxacin enhances apoptosis induced by VP-16. THP-1 (A and C) and Jurkat cells (B and C) were incubated for 24h with VP-16 and MXF as indicated and flow cytometric analysis was
performed by binding of annexin V and uptake of PI. A representative experiment is shown in (A and B). Results (mean7s.e.) of two independent experiments are shown in (C). The percentage of
annexin V-positive, PI-negative cells is indicated in the lower right quadrangle and of annexin V-positive, PI-positive cells in the upper right quadrangle. The X-axis shows log annexin V fluorescence intensity
and the Y-axis shows PI fluorescence intensity. *Po0.04 for cells treated with VP-16þMXF vs VP-16 alone.
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swith the inhibitor before the addition of 1mgml
 1 VP-16 reduced
the degree of caspase-3 activation (insert in Figure 4A).
Immunoblots performed on lysates of these cells demonstrated
that MXF enhanced the cleavage of procaspase 3 induced by
1ı `gml
 1 VP-16 in a dose-dependent manner (Figure 4B).
In Jurkat cells, as shown in Figure 4C, incubation with 1 or
3mgml
 1 VP-16 significantly enhances caspase-3 activity by 4.4-
fold (Po0.001) and by 21.3-fold (P¼0.014), respectively. The
addition of MXF to VP-16 further enhanced the activity of caspase-
3. The addition of 5, 10 or 20mgml
 1 MXF to lmgml
 1 VP-16
resulted in a 2.3-, 3.5- and 4.4-fold increase in caspase-3 activity,
respectively (P¼0.028, P¼0.05 and P¼0.05, respectively),
indicating that MXF increases the inhibition of Jurkat cell
growth, induced by VP-16, by induction of apoptosis via activation
of caspase-3 activity. Similarly, the combination of 20mgml
 1
MXF and 3mgml
 1 VP-16 led to an additional 1.45-fold increase
in caspase-3 activity (P¼0.035) (Figure 4C). Treatment of the
cells with Z-DEVD-FMK before the addition of 1mgml
 1 VP-16
reduced the degree of caspase-3 activation (inset in Figure 4C),
confirming that the caspase activity observed was specific to
caspase-3. Immunoblots performed on lysates of these cells
demonstrated that MXF enhanced the cleavage of procaspase-3
induced by 1mgml
 1 VP-16 in a dose-dependent manner
(Figure 4D).
Secretion of proinflammatory cytokines
We investigated the effect of VP-16 on the secretion of
proinflammatory cytokines by THP-1 and Jurkat cells. The
spontaneous release of IL-8 by THP-1 cells cultured for 72h was
6174pgml
 1. The addition of 5mgml
 1 MXF resulted in a three-
fold decrease in the spontaneous release of the cytokine (to
19.371.2pgml
 1)( Po0.001). Time-dependent studies performed
with THP-1 cells indicate that exposure of the cells to 1mgml
 1
VP-16 for 24–72h resulted in a 3.1–8.9-fold increase in IL-8
secretion (Po0.001) (Figure 5A). The addition 5mgml
 1 MXF to
cells cultured for 72h with 1mgml
 1 VP-16 completely abolished
the increase in IL-8 secretion induced by VP-16 (Po0.001) (data
not shown). Exposure of the cells for 24–72h to 3mgml
 1 VP-16
resulted in additional increase in IL-8 secretion up to
2318770pgml
 1 (at 72h) (Po0.001) (Figure 5A). The addition
of 5mgml
 1 MXF to cells cultured with 3mgml
 1 VP-16 induced a
time-dependent decrease in IL-8 secretion induced by VP-16 (up
to 10-fold decrease at 72h) (Po0.001). No additional decrease in
IL-8 secretion was observed in the presence of 10 or 20mgml
 1
MXF (Figure 5A). Dose-dependent studies of VP-16 on the
secretion of IL-lb and TNF-a were performed. Exposure of THP-
1 cells for 24h to 1 or 3mgml
 1 VP-16 induced an increase in the
secretion of IL-lb and TNF-a (Figure 5B and C, respectively). The
addition of MXF, even at low concentration (5mgml
 1), com-
pletely inhibited the enhanced IL-lb and TNF-a secretion induced
by 0.5 and 1mgml
 1 VP-16. The addition of 5, 10 or 20mgml
 1
MXF to cells incubated with 3mgml
 1 VP-16 decreased TNF-a
secretion by 52%, 44% and 66%, respectively (P¼o0.001 for each
concentration) (Figure 5C). In Jurkat cells, no secretion of IL-8
could be detected without stimulation with PMA and ionomycin
(data not shown). Pretreatment of the cells with 500ngml
 1
ionomycin and 1–10ngml
 1 PMA for 24h resulted in a dose-
dependent increase in IL-8 secretion (Figure 5D). Lower concen-
trations of IL-8 were detected upon pretreatment with 10ngml
 1
PMA and 5 or 50ngml
 1 ionomycin (Figure 5D). The addition of
1–3mgml
 1 VP-16 to Jurkat cells pretreated with PMA at a dose of
10ngml
 1 or lower and 500ngml
 1 ionomycin or lower had no
effect on IL-8 release from the cells (data not shown).
DISCUSSION
Several studies on the antiproliferative activity of fluoroquinolone
antibiotics have shown that quinolones such as ciprofloxacin and
fleroxacin inhibit the growth of various human tumour cells,
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Figure 4 Moxifloxacin enhances caspase-3 activation induced by VP-16. THP-1 (A) and Jurkat cells (C) were incubated with the indicated concentrations
of VP-16 and MXF for 24h and lysates were prepared. Caspase-3 activity was measured using DEVD-AMC as the substrate. The data represent the
mean7s.e. of three experiments. Effect of caspase-3 inhibitor (insert in A and C): grey column indicates control cells; white column indicates cells treated
with 1mgml
 1 VP-16. The black column cells were preincubated for 30min with Z-DEVD-FMK (caspase-3 inhibitor) before exposure to 1mgml
 1 VP-16.
*Po0.05; **Po0.012 VP-16þMXF vs VP-16-treated cells. Western blot analysis of procaspase-3. THP-1 (B) and Jurkat cells (D) were incubated in
medium (lane 1) or with 1mgml
 1 VP-16 (lanes 2–5) and MXF (5–20mgml
 1) (lanes 3–5, respectively). Lysates were prepared and samples containing
50mg protein were resolved in 12% SDS gels and electroblotted onto nitrocellulose membranes. The membranes were probed with anticaspase-3 rabbit
polyclonal antibody and with antiactin antibody.
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sincluding transitional cell carcinoma of the bladder and human
colorectal carcinoma cells (Miclau et al, 1998; Aranha et al, 2000).
El-Rayes et al (2002) reported that ciprofloxacin acts synergisti-
cally with VP-16 in hormone-resistant prostate cancer cells and
Kamat et al (1999) demonstrated that ciprofloxacin and ofloxacin
exert synergistic activity with doxorubicin in bladder cancer cell
lines.
The present study investigated, for the first time, the effect of
MXF in combination with VP-16 on the activity of human topo II
by measuring the relaxation of supercoiled pUC 19 DNA plasmid.
We have also defined the functional interaction of the drugs by
investigating their effect on the cytotoxic activity towards THP-1
and Jurkat cells.
We found that MXF alone (at a concentration of 20 or
40mgml
 1) only slightly inhibited human topo II activity, but in
combination with VP-16 it led to a significant increase in the
inhibitory effect of the anticancer drug on topo II activity. In
addition, we found that the inhibitory effect of the combined drugs
on topo II could be inhibited only by increasing the amount of the
enzyme protein in the reaction and not by adding higher
concentrations of the DNA substrate. This suggests that MXF
enhances the inhibitory effects of VP-16 on topo II by affecting the
enzyme protein in such a way that it renders it to become more
susceptible to VP-16.
Other investigators (Perrone et al, 2002) studied the inhibition
of topo II by four quinolones and ultraviolet A irradiation, and
found that MXF at various concentration up to 10mM (equivalent
to 4mgml
 1) did not show enzyme inhibitory activity in the
absence or presence of UVA irradiation. We believe that the
discrepancy between the studies may be explained by the use of
different concentrations of the drug.
To the best of our knowledge, the experiments reported here are
also the first to examine the interaction of MXF and VP-16 on the
cytotoxic activity of VP-16 and the effect of the combination on
cytokine release induced by VP-16. Our study revealed that MXF
by itself (at 20mgml
 1) induced a slight antiproliferative effect (up
to 20% decrease in cell proliferation) on THP-1 or Jurkat cells. An
additive effect was observed upon incubation of the cells with VP-
16 to significantly decrease cell proliferation. A possible explana-
tion for this additive effect is the different mechanisms of action
against topo II conferred by the two drugs. Bromberg et al (2003b)
have shown that VP-16 acts by inhibiting the ability of topo II to
ligate cleaved DNA molecules, whereas quinolones have little effect
on ligation but stimulate the forward rate of topo II-mediated DNA
cleavage. These two distinct mechanisms may work in concert and
lead to the observed additivity in the antiproliferative effects of
VP-16 and MXF. Using flow cytometric analysis to determine the
mechanism of action of the drugs, we observed that VP-16 induced
apoptosis in the two cell lines and that MXF potentiated this
apoptotic effect. This finding was supported by measuring levels of
caspase-3, which is activated during the process of apoptosis and is
one of the key enzymes required for the execution of the apoptotic
programme. The results showed that MXF significantly enhanced
VP-16-induced activation of caspase-3 in THP-1 and Jurkat cells
and that its effect was dose dependent. Western blot analysis
confirmed the enhanced proteolytic cleavage of procaspase-3
induced by the combination of MXF and VP-16. Together, these
observations indicate that MXF acts as a potentiating drug with
VP-16 to enhance VP-16’s cytotoxic effect and tumour lysis via
activation of caspase-3 activity.
An important observation is the fact that 0.5mgmg
 1 VP-16
combined with 20mgmg
 1 of MXF led to the same inhibition of
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Figure 5 Moxifloxacin decreases proinflammatory cytokine secretion induced by VP-16 in THP-1 cells. Time-dependent studies: THP-1 cells were
incubated for 24–72h with increasing concentrations of VP-16 and 5mgml
 1 MXF as indicated. The concentrations of IL-8 (A) were measured by ELISA.
Dose-dependent studies: THP-1 cells were incubated for 24h with increasing concentrations of VP-16 and MXF. The concentrations of IL-1b (B) and TNF-
a (C) in culture supernatant were measured by ELISA. The values are the mean7s.e. of four experiments performed in duplicates. *Po0.018; **Po0.008
VP-16þMXF vs VP-16-treated cells. (D) Jurkat cells were incubated for 24h with the indicated concentrations of PMA and ionomycin and the
concentration of IL-8 was measured by ELISA. The values are the mean7s.e. of four experiments performed in duplicate.
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scell proliferation as a double dose of VP-16 (1mgml
 1) alone. This
may imply a cytotoxic-drug ‘sparing effect’ by MXF. The
translation of this phenomenon in the clinical setting is that
instead of increasing the dose of the cytotoxic agent, along with its
associated toxic side effect, one may use a lower dose of the
cytotoxic agent and add the antimicrobial agent MXF with its
excellent safety profile, and obtain the same antitumour effects
with much less toxicity and adverse effects. It should also be noted,
that the concentration of MXF cited above is readily attainable in
various tissues such as colon, bladder, prostate and lung cells
following the commonly used 400mg daily oral dose of MXF.
We show in the present study that treatment of THP-1 cells with
VP-16 induced the release of the proinflammatory cytokines IL-8,
IL-1b and TNF-a. Recent studies have shown that IL-8 is a
proangiogenic cytokine regulating tumorigenesis in DLD-1 colon
cancer cells (Mizukami et al, 2005), and that it also serves as an
autocrine growth factor in human colon carcinoma cells in vitro
(Brew et al, 2000). These effects should be looked at as undesired
side effects of the drug. Chemotherapy and radiotherapy are
prescribed to cancer patients in the hope that dying cells will be
safely scavenged by phagocytic cells, such as macrophages.
However, in vitro and in vivo studies showed that phagocytosis
of VP-16-treated P388 cells by macrophages was associated with
the release of IL-8 and other cytokines, such as MIF and MIP-2
(Kawagishi et al, 2001). In addition, VP-16 and the chemo-
therapeutic agent mitomycin were also found to induce IL-8 and
TNF-a production by a human epithelial carcinoma cell line (KB
cells) that expressed platelet-activating factor receptor (Darst et al,
2004). The enhanced expression of cytokines induced by VP-16
may in part be associated with certain side effects and should be
looked upon with caution owing to the associated proangiogenic
activity of IL-8. Our results showed that MXF significantly
inhibited the VP-16-enhanced production of IL-8, TNF-a and IL-
1b in THP-1 cells, but not in Jurkat cells. Accordingly, Aceves et al
(2004) reported a different pattern of gene expression in THP-1
and Jurkat cells on their exposure to chemotherapeutic drugs. This
may suggest that the inhibitory effect of MXF on the release of
proinflammatory cytokines by cells is tumour cell specific.
The inhibitory effect of MXF on cytokine secretion from THP-1
cells also confirms our previous observations of MXF inhibition of
the synthesis of proinflammatory cytokines in THP-1 cells and
human peripheral blood monocytes stimulated with LPS-phorbol
myristate acetate (Weiss et al, 2004) or Aspergillus fumigatus
(Shalit et al, 2006). Additionally, MXF inhibited NF-kB and
mitogen-activated protein kinase activation in THP-1 cells and in a
human respiratory epithelial cell line (Weiss et al, 2004; Werber
et al, 2005). Using a murine model of Candida pneumonia in
immune-suppressed animals, we found that MXF exerted a
protective anti-inflammatory effect, resulting in a marked decrease
in bronchopneumonia and enhanced survival. This protective
efficacy was associated with a significant reduction in IL-8 and
TNF-a in lung homogenates and an inhibition of NF-kB nuclear
mobilisation in alveolar macrophages and lung epithelial cells
(Shalit et al, 2002).
Nuclear factor-kB is a well-known mediator of inflammatory
cytokines (Won et al, 2005), and it was shown to be activated
during apoptosis following cell incubation with a variety of agents
including VP-16 (Usami et al, 1998). Based on our previous and
current observations, it seems plausible that MXF decreases VP-
16-induced proinflammatory cytokine secretion in THP-1 cells via
inhibition of NF-kB activation.
In summary, this study demonstrates an important role for MXF
in enhancing the cytotoxic effects of VP-16 whereas, at the same
time, decreasing VP-16-induced proinflammatory cytokine secre-
tion from cells, which may be harmful during chemotherapeutic
treatment. Our results suggest that MXF may be a valuable new
addition to chemotherapeutic armamentarium, simultaneously
improving the cytotoxic activity while reducing the side effects of
VP-16 and similar agents.
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